BPC 157 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-09-15. Numbers and descriptions here follow the published literature rather than marketing material.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
| Property | Value | Notes |
|---|---|---|
| Molar mass | Approximately 1419.5 g/mol | Calculated from the reported 15-residue sequence |
| Molecular formula | C62H98N16O22 | Based on the same sequence |
| Appearance | White to off-white powder | Typical of a lyophilized preparation |
| Solubility class | Freely soluble in water | Also dissolves in saline solutions |
| Typical storage temperature | Minus 20 degrees Celsius, dry | Refrigeration advised after reconstitution |
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
=== Bibliography === Barrett, Kim E. (2019). Ganong's review of medical physiology. Barman, Susan M.,, Brooks, Heddwen L., Yuan, Jason X.-J. (26th ed.). New York. ISBN 978-1-260-12240-4. OCLC 1076268769.{{cite book}}: CS1 maint: location missing publisher (link) Beger HG, ed. (2018). The pancreas: an integrated textbook of basic science, medicine, and surgery (third ed.). Hoboken, NJ. ISBN 978-1-119-18841-4. OCLC 1065547789.{{cite book}}: CS1 maint: location missing publisher (link) Kasper D, Fauci A, Hauser S, Longo D, Jameson J, Loscalzo J (2015). Harrison's Principles of Internal Medicine (19 ed.). McGraw-Hill Professional. ISBN 978-0-07-180215-4. Ralston SH, Penman ID, Strachan MW, Hobson RP, eds. (2018). Davidson's principles and practice of medicine (23rd ed.). Elsevier. ISBN 978-0-7020-7028-0. Standring, Susan; Borley, Neil R.; et al., eds. (2008). Gray's anatomy: the anatomical basis of clinical practice (40th ed.). London: Churchill Livingstone. ISBN 978-0-8089-2371-8. Standring, Susan, ed. (2016). Gray's anatomy: the anatomical basis of clinical practice (41st ed.). Philadelphia. ISBN 978-0-7020-5230-9. OCLC 920806541.{{cite book}}: CS1 maint: location missing publisher (link) Young, Barbara; O'Dowd, Geraldine; Woodford, Phillip (2013). Wheater's functional histology: a text and colour atlas (6th ed.). Philadelphia: Elsevier. ISBN 978-0-7020-4747-3.
==== Keeping the tradition alive ==== Family members often gather to cook lefse as a group effort because the process is more enjoyable as a traditional holiday activity. This gathering also provides training to younger generations keeping the tradition alive. The Sons of Norway have lodges to teach making lefse to younger generations. A lodge in Vancouver, Washington, uses up to 60 pounds (27 kg) of potatoes to make lefse every month. While lefse used to be eaten as a snack food, it is now more often made in large quantities for such lutefisk dinners. Some professional lefse makers can roll 85 to 100 lefse per hour, or even up to 140.
== Overview == VersaCold started in 1946 as B.C. Ice & Cold Storage Co., serving Vancouver’s fishing industry. In the decades that followed, the company expanded steadily east. By the 1980s the company had established a strong base in the West with eight facilities in BC, Alberta and Washington. A series of mergers and acquisitions throughout the 1990s put VersaCold on the continental and, by 2005, global map, as the purchase of P&O Cold Storage added operations in the US, Australia, New Zealand and Argentina. In 2010, VersaCold sold its offshore operations and returned to its Canadian roots. VersaCold is jointly owned by Toronto-based private equity firm KingSett Capital and Quebec-based investor Ivanhoé Cambridge. Today, VersaCold operates the largest temperature-sensitive logistics network in Canada, with 27 temperature-controlled warehouses and distribution centres and a fleet of trucks providing local, regional, national and international transportation across Canada and the United States. In August 2022, American multinational logistics chain Lineage announced its acquisition of VersaCold for an undisclosed sum.
Sources: en.wikipedia.org
=== 1984 === January: U.S. President Ronald Reagan outlines foreign policy which reinforces his previous statements. January 1: Brunei gains independence from the UK. February 13: Konstantin Chernenko is named General Secretary of the Soviet Communist Party. May 24: the U.S. Congress ratifies the Boland Amendment banning U.S. aid to the contras. June 1–10: Operation Blue Star begins. July 28: various allies of the Soviet Union boycott the 1984 Summer Olympics (July 28 – August 12) in Los Angeles. August 11: during a microphone sound check for his weekly radio address, President Ronald Reagan jokes about bombing the Soviet Union. "My fellow Americans", Reagan says. "I'm pleased to tell you today that I've signed legislation that will outlaw Russia forever. We begin bombing in five minutes." The quip is not aired but is leaked to the press. The Soviet Union temporarily puts its defense forces on high alert. October 19: Father Jerzy Popiełuszko assassinated. October 31: Indira Gandhi assassinated. December 16: Margaret Thatcher and the UK government, in a plan to open new channels of dialog with Soviet leadership candidates, meet with Mikhail Gorbachev at Chequers.
== Articles == Hoyle, F. and Wickramasinghe, N.C., 1962. On graphite particles as interstellar grains, Mon.Not.Roy.Astr.Soc. 124, 417-433 Hoyle, F.; Wickramasinghe, N.C. (1969). "Interstellar Grains". Nature. 223 (5205): 450–462. Bibcode:1969Natur.223..459H. doi:10.1038/223459a0. S2CID 4209522. Wickramasinghe, N. C. (1974). "Formaldehyde polymers in interstellar space". Nature. 252 (5483): 462–463. doi:10.1038/252462a0. ISSN 0028-0836. Retrieved 20 January 2026. Wickramasinghe, N.C. (1999). "Formaldehyde Polymers in Interstellar Space". Astrophysics and Space Science. 268 (1–3): 111–114. doi:10.1023/A:1002448820097. ISSN 0004-640X. Retrieved 20 January 2026. Wickramasinghe, N.C.; Hoyle, F.; Brooks, J.; Shaw, G. (1977). "Prebiotic polymers and infrared spectra of galactic sources". Nature. 269 (5630): 674–676. Bibcode:1977Natur.269..674W. doi:10.1038/269674a0. S2CID 4266722. Hoyle, F. and Wickramasinghe, N.C., 1977. Identification of the λ2,200A interstellar absorption feature, Nature 270, 323-324 F., Hoyle; N. C., Wickramasinghe (4 November 1976). "Primitive grain clumps and organic compounds in carbonaceous chondrites" (PDF). Nature. 264 (5581): 45–46. Bibcode:1976Natur.264...45H. doi:10.1038/264045a0. Retrieved 18 January 2013. Hoyle, F. and Wickramasinghe, N.C., 1977. Polysaccharides and infrared spectra of galactic sources, Nature 268, 610-612 Hoyle, F.; Wickramasinghe, N.C. (1979). "On the nature of interstellar grains". Astrophysics and Space Science. 66 (1–3): 77–90. Bibcode:1999Ap&SS.268..249H. doi:10.1023/A:1002462602776. S2CID 189820472.
The defence submitted that there was no case to answer on the air‑embolism allegations, arguing that the prosecution's experts lacked sufficient clinical experience, that the research basis for air embolism was inconsistent, and that expert descriptions of the condition varied. Goss ruled that there was "a sufficient body of accepted medical opinion" to allow the allegation to be considered by the jury.
Sources: en.wikipedia.org
=== Breakdown === The liver is responsible for the breakdown of insulin and other hormones. The liver breaks down bilirubin via glucuronidation, facilitating its excretion into bile. The liver is responsible for the breakdown and excretion of many waste products. It plays a key role in breaking down or modifying toxic substances (e.g., methylation) and most medicinal products in a process called drug metabolism. This sometimes results in toxication, when the metabolite is more toxic than its precursor. Preferably, the toxins are conjugated to avail excretion in bile or urine. The liver converts ammonia into urea as part of the ornithine cycle or the urea cycle, and the urea is excreted in the urine.
It hurt me a lot to see the mothers of the deceased babies with a little piece of paper. You say "your child died", I don't know where is the need to script them. I am sorry, but I found that shocking. This never happened to me and I hope that I will never have to live it again, but all the script... no, no. Whatever happens, I am absolutely in peace. I never did anything to those children. I don't know how to say this again, I don't know how many times. I am innocent of what I am being accused of. You don't have any serial killer here. I love children. On 18 June, previous to the verdict, Agüero's parents released a statement calling for their daughter's acquittal, saying (against medical evidence) that the babies were "not healthy" and that they "died for other causes." Hours later, the jury returned a verdict of guilty on all counts and sentenced her to life in prison.
My energy comes from my diet. Breakfast is 10 eggs and two to three pounds of bacon. Between meals, I eat lots of candy. In the morning, it will be several 3 Musketeers and/or Snickers bars; I need them for energy. Lunch, at 1 or 2 PM, is a double meal of a Polish pork chop, sauerkraut and potatoes. An hour later, I work out, then take lots of supplements: magnesium, creatine,[sic] amino acids, all that stuff, and more chocolate. Dinner is whatever meat I can grab—steaks, pork chops, bacon—plus more sauerkraut and potatoes. At 9 or 10 PM, I work out again. Afterward, I have a protein shake and more chocolate. At 3 or 4 AM, I wake up and have more chocolate, then go back to sleep until morning. He said for MTV that he prefers Polish cuisine. When he has some time he often cooks himself, as he does not particularly fancy meals from restaurants. He often eats bigos, Polish soups, Polish sausages and typical Polish dinners with cooked potatoes, 200–300 g of meat and some salads (usually cucumber salad). In an interview at the beginning of his world strongman career he said that his supplements, training, massages, etc. costs him approximately 6000 złoty (c. U.S. $2,000) per month.
Sources: en.wikipedia.org
It does not occur in the form that is supplied commercially. Its sequence matches a fragment of a larger gastric protein, and the research material is produced synthetically in a laboratory. The fragment described in the early literature is generally the same synthetic pentadecapeptide.
It marks the position of the sequence inside the original protein. The label traces back to early work fractionating gastric juice and describing a body protection compound. The figure does not refer to molecular weight or to the count of amino acids.
No. The sequence has no cysteine residues, so disulfide bridges cannot form. That feature makes it easier to handle than many small proteins that depend on multiple cysteines for structure.
Human data are limited. Most evidence comes from animal experiments and from small or uncontrolled reports. The absence of large trials means clinical effects and safety are not firmly established.